Marked improvement in scleromyxedema with high-dose intravenous immunoglobulin;Deutliche besserung eines skleromyxödem arndt-gottron durch hoch dosierte intravenöse immunglobuline

Hautarzt

Volumn 58, Issue 6, 2007, Pages 525-528

  Topf, S ^a,b   Simon Jr , M ^a   Schell, H ^a   Luftl M ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Prof Steinkraus und Partner   (Germany)

Author keywords

Intravenous immunoglobulin; Isotretinoin; Scleromyxedema; UVA 1

Indexed keywords

IMMUNOGLOBULIN;

ADULT; ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOTHERAPY; JOINT MOBILITY; MONOCLONAL IMMUNOGLOBULINEMIA; PAPULE; SCLEROMYXEDEMA; SKIN INDURATION;

FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; SCLEROMYXEDEMA; TREATMENT OUTCOME;

EID: 34250321375     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-006-1261-1     Document Type: Article

References (12)

1. Bachot N, Revuz J, Roujeau JC (2003) Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 139: 33-36
2. Bata-Csörgö Z, Husz S, Foldes M et al. (1999) Scleromyxoedema. J Am Acad Dermatol 41: 343-346
3. Godby A, Bergstresser P, Chaker B, Pandya A (1998) Fatal Scleromyxoedema: report of a case and review of the literature. J Am Acad Dermatol 38: 289-294
4. Karim A, Lawlor F, Black M (2004) Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin. Clin Exp Dermatol 29: 317
5. Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobuline. N Engl J Med 345: 747-755
6. Kulczycki A, Nelson M, Eisen A, Heffeman M (2003) Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin. Br J Dermatol 149: 1276-1281
7. Lister RK, Jolles S, Whittaker S et al. (2000) Scleromyxoedema: response to high-dose intravenous immunoglobulin (hdIVIG). J Am Acad Dermatol 43: 403-408
8. Mydlarski P, Mittmann N, Shear H (2004) Intravenous immunoglobulin: use in dermatology. Skin Therapy Lett 9(5): 1-6
9. Righi A, Schiavon F, Jablonska S et al. (2002) Intravenous immunoglobulins control scleromyxoedema. Ann Rheum Dis 61: 59-61
10. Ruetter A, Luger T (2001) High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol 44: 1010-1024
11. Ruetter A, Luger T (2004) Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease. Am J Clin Dermatol 5: 153-160
12. Schirren C, Betke M, Eckert F, Przybilla B (1992) Skleromyxödem Arndt-Gottron. Hautarzt 45: 152-157